DGAP-News: Biotest AG / Key word(s): Miscellaneous Biotest AG: Biotest opens new plasma collection centre in Vermillion, South Dakota, USA 28.09.2016 / 09:16 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- / PRESS RELEASE Biotest opens new plasma collection centre in Vermillion, South Dakota, USA - 13 plasma collection centres in Europe - 21 in the US to ensure long-term plasma supply Dreieich, 28 September 2016. Biotest Pharmaceuticals Corporation (BPC), Boca Raton, USA, a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to announce the addition of its newest plasma collection centre located at Vermillion, South Dakota, USA. The state-of-the-art facility officially opened its doors for business on September 26, 2016 and brings the total number of BPC's plasma collection centres to 21. "The opening of our 21st centre further reinforces our continued commitment to the expansion of our existing network of plasma collection centres. We are fully dedicated to better serve the thousands of patients worldwide who rely on plasma- based therapies", said Ileana Carlisle, BPC's Chief Executive Officer. BPC has invested approximately EUR1.6 million in the construction of this facility. The company expects to add over 40 jobs to the Vermillion local economy and currently has employment opportunities available for medical personnel. About human blood plasma Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest is one of the world's six largest manufacturers of plasma protein products. About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,400 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. IR contact Dr. Monika Buttkereit phone: +49-6103-801-4406 email: [email protected] PR contact Dirk Neumüller phone: +49-6103-801-269 email: [email protected] Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany www.biotest.de Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Preference shares: securities' ID No. 522723; ISIN DE0005227235 Listing: Prime Standard Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. --------------------------------------------------------------------------- 28.09.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: [email protected] Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 505879 28.09.2016